STOCK TITAN
  1. Home
  2. Sec-filings
  3. CYTK
  4. [Form 4] CYTOKINETICS INC Insider Trading Activity

Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares, retains large stake

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Cytokinetics Inc President & CEO Robert I. Blum reported an open-market sale of common stock. He sold 7,500 shares of Cytokinetics common stock at $65.38 per share on April 15, 2026.

After this transaction, Blum directly owns 415,330 shares of Cytokinetics common stock. He also has indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.

Positive

  • None.

Negative

  • None.
Insider Blum Robert I
Role President & CEO
Sold 7,500 shs ($490K)
Type Security Shares Price Value
Sale Common Stock 7,500 $65.38 $490K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 415,330 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1)
Footnotes (1)
  1. Shares held by The Bridget Blum 2003 Irrevocable Trust. Shares held by The Brittany Blum 2003 Irrevocable Trust.
Shares sold 7,500 shares Open-market sale of common stock on April 15, 2026
Sale price per share $65.38 per share Price for 7,500 Cytokinetics common shares sold
Direct holdings after sale 415,330 shares Common stock directly owned by Robert I. Blum after transaction
Indirect holdings – Bridget Blum Trust 2,083 shares Common stock held by The Bridget Blum 2003 Irrevocable Trust
Indirect holdings – Brittany Blum Trust 2,083 shares Common stock held by The Brittany Blum 2003 Irrevocable Trust
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Irrevocable Trust financial
"Shares held by The Bridget Blum 2003 Irrevocable Trust."
indirect ownership financial
""direct_or_indirect": "I","nature_of_ownership": "by Trust 1""
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Blum Robert I
(Last)(First)(Middle)
350 OYSTER POINT BLVD
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/15/2026S7,500D$65.38415,330D
Common Stock2,083Iby Trust 1(1)
Common Stock2,083Iby Trust 2(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
2. Shares held by The Brittany Blum 2003 Irrevocable Trust.
/s/ John O. Faurescu, attorney-in-fact for Mr. Blum04/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Cytokinetics (CYTK) report for Robert Blum?

Cytokinetics reported that President & CEO Robert I. Blum sold 7,500 shares of common stock. The open-market sale was executed on April 15, 2026, at a price of $65.38 per share, according to the Form 4 filing.

How many Cytokinetics (CYTK) shares does Robert Blum hold after this sale?

After the reported sale, Robert I. Blum directly holds 415,330 shares of Cytokinetics common stock. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.

What was the sale price in Robert Blum’s Cytokinetics (CYTK) Form 4?

Robert I. Blum’s Form 4 shows an open-market sale of Cytokinetics common stock at $65.38 per share. The transaction covered 7,500 shares of common stock on April 15, 2026, as disclosed in the filing.

Are any of Robert Blum’s Cytokinetics (CYTK) shares held indirectly?

Yes. The Form 4 shows 2,083 Cytokinetics shares held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held indirectly by The Brittany Blum 2003 Irrevocable Trust, in addition to Blum’s direct holdings.

What type of transaction code appears in Robert Blum’s Cytokinetics (CYTK) Form 4?

The Form 4 lists transaction code “S” for Robert I. Blum’s trade, indicating a sale in an open-market or private transaction. The code applies to the 7,500 shares of Cytokinetics common stock sold at $65.38 per share.